Next-Generation Nanobody Immunotherapy Targeting CD274 and TGF for Solid Tumors

VHH-P790 is a humanized single-domain antibody (nanobody) engineered to target both CD274 molecule (CD274) and transforming growth factor (TGF). This innovative construct is currently undergoing biological testing and presents significant promise for the treatment of solid tumor indications. By integrating specific recognition domains for CD274 molecule (CD274) and transforming growth factor, VHH-P790 leverages advanced molecular strategies to disrupt immunosuppression within the tumor microenvironment. Its unique dual-targeting approach supports enhanced immune activation and tumor cell targeting, setting the stage for a novel therapeutic avenue in solid tumor management.

Licensing Opportunity

VHH-P790 is available for licensing and collaborative development. We invite global partners and industry stakeholders to explore strategic opportunities for co-development and commercialization of this next-generation immunotherapeutic program.

Development Phase

Modality

VHH-P790 utilizes a modular nanobody architecture, consisting of a humanized single-domain antibody that targets programmed death-ligand 1, fused with transforming growth factor beta receptor 2 mutants. As a nanobody, VHH-P790 is characterized by its small molecular weight, robust structural stability, and superior tissue penetration. These advantages enable more effective infiltration into solid tumor masses, allowing for precise target engagement within challenging tumor niches. The compact structure also facilitates manufacturability and flexibility in drug design, which are crucial for developing novel therapeutics for solid tumors with complex microenvironments.

Target

CD274 and TGF are critical immunomodulatory molecules implicated in tumor immune evasion and progression. CD274 is a cell surface protein expressed predominantly on tumor cells and immune cells within the tumor microenvironment, acting as an important immune checkpoint molecule. TGF is a multifunctional regulatory cytokine involved in cell proliferation, migration, and the modulation of immune responses, particularly in the context of cancer. Both CD274 and TGF contribute to a suppressive milieu that hinders effective antitumor immunity in solid tumors. Targeting CD274 and TGF simultaneously offers a strategic approach by disrupting synergistic pathways of immune suppression and tumor growth. VHH-P790, by focusing on CD274 and TGF, stands as a compelling asset in the pursuit of next-generation immuno-oncology therapies.

Mechanism of Action

VHH-P790 exerts its therapeutic effect through dual inhibition of immune checkpoint and transforming growth factor pathways. By binding CD274, VHH-P790 blocks the interaction with programmed death receptors on effector immune cells, thereby reactivating antitumor immune responses. Concurrently, the fusion to transforming growth factor beta receptor mutants allows sequestration or neutralization of TGF signaling, further relieving immune suppression and impairing tumor-promoting processes. This combined mechanism fosters an environment conducive to robust immune-mediated tumor cell eradication. Furthermore, the single-domain antibody platform underpinning VHH-P790 offers significant potential for future expansion into multi-specific antibodies, antibody-drug conjugates, and bispecific modalities, broadening its therapeutic applications.

Solid Tumor

Solid tumors encompass a diverse group of malignancies arising from epithelial, mesenchymal, or other tissue origins, characterized by the formation of a discrete mass. Globally, solid tumors represent a leading cause of morbidity and cancer-related mortality. Standard treatment modalities include surgical resection, radiation, chemotherapy, and targeted therapies, with immune checkpoint inhibitors gaining prominence in recent years. However, limitations such as drug resistance, tumor heterogeneity, and immune evasion persist, contributing to poor long-term outcomes in many patients. Notably, current therapies often struggle to overcome the immunosuppressive mechanisms orchestrated by the tumor microenvironment, including those mediated by checkpoint molecules and transforming growth factors. VHH-P790, through dual targeting of CD274 and TGF, holds the potential to directly confront these barriers, offering new hope for improved efficacy and durable responses in the management of solid tumors.